Search Results

Your search for Vamsidhar Velcheti, MD, and Roy Herbst, MD, PhD,Vamsidhar Velcheti, MD, and Roy Herbst, MD, PhD matches 1 pages

Showing 1 - 1

By Vamsidhar Velcheti, MD, and Roy Herbst, MD, PhD / July 10, 2015

Pembrolizumab in Advanced NSCLC: The Promise of Immune Checkpoint Inhibitors

Drugs targeting the immune-checkpoint pathways have shown promising activity in non–small cell lung cancer (NSCLC). In a recent article in The New England Journal of Medicine, Garon and colleagues reported the results of the KEYNOTE-001 clinical trial evaluating single-agent pembrolizumab...

Apr

Today In Oncology

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being